Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent influenza split vaccine (MDCK cells)
- Development stage
- Preclinical
- Lead developer
- Shanghai Rongsheng Biotech
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent influenza split vaccine (MDCK cells) is an inactivated split-virion vaccine developed by Shanghai Rongsheng Biotech for the prevention of seasonal influenza. Unlike traditional influenza vaccines produced in embryonated chicken eggs, this vaccine is manufactured using Madin-Darby Canine Kidney (MDCK) cell culture technology. This production platform offers advantages such as increased scalability and a reduced risk of egg-adaptive mutations that can sometimes affect vaccine efficacy. The vaccine is designed to target four strains of the influenza virus, typically including two influenza A strains (H1N1 and H3N2) and two influenza B strains (Victoria and Yamagata lineages). Its mechanism of action involves inducing strain-specific protective antibody responses, primarily targeting the viral hemagglutinin protein, to provide immunity against circulating influenza viruses.
- Other names
- 四价流感病毒裂解疫苗（MDCK细胞）Quadrivalent Influenza Split Vaccine (MDCK cells)inactivated split vaccine (MDCK cells)
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on quadrivalent influenza split vaccine (MDCK cells).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent influenza split vaccine (MDCK cells).